Nanobiotix S.A. - ADSs (NBTX)
41.23
+0.00 (0.00%)
NASDAQ· Last Trade: Aug 31st, 9:38 AM EDT
One of J&J's investments stands head-and-shoulders above the rest.
Via The Motley Fool · August 31, 2026
It has grown wildly, and it could keep growing.
Via The Motley Fool · November 24, 2025
Via Benzinga · November 11, 2025
Via Benzinga · October 28, 2025
Via Benzinga · October 28, 2025
Via Benzinga · October 28, 2025
Via Benzinga · October 27, 2025
Via Benzinga · October 27, 2025
Via Benzinga · October 27, 2025
Via Benzinga · October 20, 2025
Via Benzinga · October 15, 2025
Via Benzinga · October 14, 2025
Via Benzinga · October 14, 2025
Via Benzinga · October 14, 2025
Via Benzinga · October 13, 2025
Via Benzinga · October 13, 2025
Via Benzinga · October 13, 2025
Via Benzinga · October 10, 2025
Via Benzinga · October 10, 2025
Via Benzinga · October 8, 2025
Paris, France – October 2, 2025 – Nanobiotix (NASDAQ: NBTX) witnessed a significant surge in its stock price today, jumping 11.6%, following the announcement of highly encouraging initial data from a Phase 1 study of its lead product, JNJ-1900 (NBTXR3), in patients with locally advanced esophageal adenocarcinoma. This pivotal development, revealed
Via MarketMinute · October 2, 2025
Via Benzinga · October 2, 2025
Via Benzinga · October 2, 2025
Via Benzinga · October 2, 2025
Nanobiotix reported updated Phase 1 trial data for JNJ-1900 in head and neck cancer, showing strong disease control and survival outcomes.
Via Benzinga · September 30, 2025